SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001564590-22-019084
Filing Date
2022-05-10
Accepted
2022-05-10 08:05:39
Documents
14
Period of Report
2022-05-10
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K prld-8k_20220510.htm   iXBRL 8-K 39268
2 EX-99.1 prld-ex991_75.htm EX-99.1 203805
3 GRAPHIC gpqtchjqkm0p000001.jpg GRAPHIC 9453
  Complete submission text file 0001564590-22-019084.txt   397880

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA prld-20220510.xsd EX-101.SCH 5577
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE prld-20220510_lab.xml EX-101.LAB 19308
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE prld-20220510_pre.xml EX-101.PRE 11474
8 EXTRACTED XBRL INSTANCE DOCUMENT prld-8k_20220510_htm.xml XML 3550
Mailing Address 200 POWDER MILL ROAD WILMINGTON DE 19803
Business Address 200 POWDER MILL ROAD WILMINGTON DE 19803 (302) 547-3768
Prelude Therapeutics Inc (Filer) CIK: 0001678660 (see all company filings)

IRS No.: 811384762 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39527 | Film No.: 22907458
SIC: 2834 Pharmaceutical Preparations